Cargando…

Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity

BACKGROUND: To evaluate association between von Willebrand factor (vWF) activity, inflammation markers, disease activity, and subclinical atherosclerosis in patients with rheumatoid arthritis (RA) and low cardiovascular risk. METHODS: Above mentioned parameters were determined in blood samples of 74...

Descripción completa

Detalles Bibliográficos
Autores principales: Ristić, Gorica G., Subota, Vesna, Lepić, Toplica, Stanisavljević, Dejana, Glišić, Branislava, Ristić, Arsen D., Petronijević, Milan, Stefanović, Dušan Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527675/
https://www.ncbi.nlm.nih.gov/pubmed/26247590
http://dx.doi.org/10.1371/journal.pone.0130462
_version_ 1782384595883261952
author Ristić, Gorica G.
Subota, Vesna
Lepić, Toplica
Stanisavljević, Dejana
Glišić, Branislava
Ristić, Arsen D.
Petronijević, Milan
Stefanović, Dušan Z.
author_facet Ristić, Gorica G.
Subota, Vesna
Lepić, Toplica
Stanisavljević, Dejana
Glišić, Branislava
Ristić, Arsen D.
Petronijević, Milan
Stefanović, Dušan Z.
author_sort Ristić, Gorica G.
collection PubMed
description BACKGROUND: To evaluate association between von Willebrand factor (vWF) activity, inflammation markers, disease activity, and subclinical atherosclerosis in patients with rheumatoid arthritis (RA) and low cardiovascular risk. METHODS: Above mentioned parameters were determined in blood samples of 74 non-diabetic, normotensive, female subjects, with no dyslipidemia(42 patients, 32 matched healthy controls, age 45.3±10.0 vs. 45.2±9.8 years). Intima-media thickness (IMT) was measured bilaterally, at common carotid, bifurcation, and internal carotid arteries. Subclinical atherosclerosis was defined as IMT>IMT(mean)+2SD in controlsat each carotid level and atherosclerotic plaque as IMT>1.5 mm. Majority of RA patients were on methotrexate (83.3%), none on steroids >10 mg/day or biologic drugs. All findings were analysed in the entire study population and in RA group separately. RESULTS: RA patients with subclinical atherosclerosis had higher vWF activity than those without (133.5±69.3% vs. 95.3±36.8%, p<0.05). Predictive value of vWF activity for subclinical atherosclerosis was confirmed by logistic regression. vWF activity correlated significantly with erythrocyte sedimentation rate, fibrinogen, modified disease activity scores (mDAS28–ESR, mDAS28–CRP), modified Health Assessment Questionnaire (p<0.01 for all), duration of smoking, number of cigarettes/day, rheumatoid factor concentration (p<0.05 for all), and anti-CCP antibodies (p<0.01). In the entire study population, vWF activity was higher in participants with subclinical atherosclerosis (130±68% vs. 97±38%, p<0.05) or atherosclerotic plaques (123±57% vs. 99±45%, p<0.05) than in those without. Duration of smoking was significantly associated with vWF activity (β 0.026, p = 0.039). CONCLUSIONS: We demonstrated association of vWF activity and subclinical atherosclerosis in low-risk RA patients as well as its correlation with inflammation markers, all parameters of disease activity, and seropositivity. Therefore, vWF might be a valuable marker of early atherosclerosis in RA patients.
format Online
Article
Text
id pubmed-4527675
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45276752015-08-12 Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity Ristić, Gorica G. Subota, Vesna Lepić, Toplica Stanisavljević, Dejana Glišić, Branislava Ristić, Arsen D. Petronijević, Milan Stefanović, Dušan Z. PLoS One Research Article BACKGROUND: To evaluate association between von Willebrand factor (vWF) activity, inflammation markers, disease activity, and subclinical atherosclerosis in patients with rheumatoid arthritis (RA) and low cardiovascular risk. METHODS: Above mentioned parameters were determined in blood samples of 74 non-diabetic, normotensive, female subjects, with no dyslipidemia(42 patients, 32 matched healthy controls, age 45.3±10.0 vs. 45.2±9.8 years). Intima-media thickness (IMT) was measured bilaterally, at common carotid, bifurcation, and internal carotid arteries. Subclinical atherosclerosis was defined as IMT>IMT(mean)+2SD in controlsat each carotid level and atherosclerotic plaque as IMT>1.5 mm. Majority of RA patients were on methotrexate (83.3%), none on steroids >10 mg/day or biologic drugs. All findings were analysed in the entire study population and in RA group separately. RESULTS: RA patients with subclinical atherosclerosis had higher vWF activity than those without (133.5±69.3% vs. 95.3±36.8%, p<0.05). Predictive value of vWF activity for subclinical atherosclerosis was confirmed by logistic regression. vWF activity correlated significantly with erythrocyte sedimentation rate, fibrinogen, modified disease activity scores (mDAS28–ESR, mDAS28–CRP), modified Health Assessment Questionnaire (p<0.01 for all), duration of smoking, number of cigarettes/day, rheumatoid factor concentration (p<0.05 for all), and anti-CCP antibodies (p<0.01). In the entire study population, vWF activity was higher in participants with subclinical atherosclerosis (130±68% vs. 97±38%, p<0.05) or atherosclerotic plaques (123±57% vs. 99±45%, p<0.05) than in those without. Duration of smoking was significantly associated with vWF activity (β 0.026, p = 0.039). CONCLUSIONS: We demonstrated association of vWF activity and subclinical atherosclerosis in low-risk RA patients as well as its correlation with inflammation markers, all parameters of disease activity, and seropositivity. Therefore, vWF might be a valuable marker of early atherosclerosis in RA patients. Public Library of Science 2015-08-06 /pmc/articles/PMC4527675/ /pubmed/26247590 http://dx.doi.org/10.1371/journal.pone.0130462 Text en © 2015 Ristić et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ristić, Gorica G.
Subota, Vesna
Lepić, Toplica
Stanisavljević, Dejana
Glišić, Branislava
Ristić, Arsen D.
Petronijević, Milan
Stefanović, Dušan Z.
Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity
title Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity
title_full Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity
title_fullStr Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity
title_full_unstemmed Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity
title_short Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity
title_sort subclinical atherosclerosis in patients with rheumatoid arthritis and low cardiovascular risk: the role of von willebrand factor activity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527675/
https://www.ncbi.nlm.nih.gov/pubmed/26247590
http://dx.doi.org/10.1371/journal.pone.0130462
work_keys_str_mv AT risticgoricag subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity
AT subotavesna subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity
AT lepictoplica subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity
AT stanisavljevicdejana subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity
AT glisicbranislava subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity
AT risticarsend subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity
AT petronijevicmilan subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity
AT stefanovicdusanz subclinicalatherosclerosisinpatientswithrheumatoidarthritisandlowcardiovascularrisktheroleofvonwillebrandfactoractivity